Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Research Professor. Dr. Stojanovich’s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the “CURRENT CONTENSTS” or “Science citation index”, like LUPUS REWIEWER DATABAS, Cellular and Molecular Neurobiology, The Journal of Vaccine <email@example.com , The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of “the European Forum on Antiphospholipid Antibodies”, “Multicenter studies antiphospholipid antibodies, infections and autoimmune diseases”. She is a mentor/ Supervisor ships a numbers of post-doc students. She was in Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars and Symposia; member of the Steering Committee of the “(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)”, and EULAR Honorary Member; chairman in the International Congress “Antiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definition”, 2013, “GRANT 2015” of the EUROPEAN STROKE CONFERENCE » for “excellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committees”, and presented at the 24th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company., MD, PhD, FRCP, are willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (“Lilly”), in connection with the development of Tabalumab also known as LY2439821. Co- Chairman and the lector “LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of EULAR«: Belgrade, 18TH MARCH 2016, www.lupus-academy.org. Member of the American Association for the Advancement of Science (AAAS) from 2017. Professor Ljudmila Stojanovich’ Impact Point is 300.14, and number of citattions is 1,444.